Daptomycin — Complete Research Guide (2026)

Last updated 2026-06-30

What is Daptomycin?

Daptomycin is a cyclic lipopeptide antibiotic derived from Streptomyces roseosporus, active only against Gram-positive bacteria including MRSA, vancomycin-resistant enterococci and other resistant staphylococci and streptococci. Unlike most peptides in this encyclopedia it is a fully regulator-approved medicine (FDA 2003, marketed as Cubicin; also EMA-approved).

It is approved for complicated skin and skin-structure infections and for Staphylococcus aureus bloodstream infection (bacteraemia), including right-sided infective endocarditis. The evidence base is strong: approval rests on human randomized controlled trials rather than preclinical data.

A critical labelled limitation is that daptomycin must NOT be used to treat pneumonia, because pulmonary surfactant binds and inactivates the drug, and it failed in community-acquired pneumonia trials.

How does Daptomycin work?

Daptomycin inserts into the bacterial cytoplasmic membrane in a calcium-dependent manner and aggregates, causing membrane depolarisation, potassium efflux and rapid, concentration-dependent bactericidal killing without lysing the cell.

This membrane-targeting mechanism is distinct from beta-lactams, glycopeptides and oxazolidinones, which is why it retains activity against many multidrug-resistant Gram-positive organisms.

What does the research say about Daptomycin?

• In an open-label randomized trial, daptomycin was non-inferior to standard therapy for S. aureus bacteraemia and right-sided endocarditis. ^[1]
• In pooled phase-3 randomized trials, daptomycin was as effective as standard comparator therapy for complicated skin and skin-structure infections. ^[2]
• In a three-year clinical program, high-dose intravenous daptomycin was generally well tolerated, with reversible creatine phosphokinase (CPK) elevation the principal monitored toxicity. ^[5]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

• [1] Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus — Fowler VG Jr et al., New England Journal of Medicine 2006. (Open-label randomized controlled trial (n=246))
• [2] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections — Arbeit RD et al., Clinical Infectious Diseases 2004. (Pooled phase-3 randomized controlled trials)
• [3] Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections — Steenbergen JN et al., Journal of Antimicrobial Chemotherapy 2005. (Review)
• [4] Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports — Kim PW et al., Drug Safety 2012. (Literature review + pharmacovigilance analysis)
• [5] Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program — Figueroa DA et al., Clinical Infectious Diseases 2009. (Observational clinical program)
• [6] Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy — Kido K et al., American Journal of Health-System Pharmacy 2019. (Clinical study)

Dosing context

Daptomycin is a hospital-administered intravenous antibiotic dosed once daily on a milligram-per-kilogram basis, with the dose selected by indication and adjusted for renal function; it is not an oral or self-administered agent.

This is descriptive context only and not a dosing recommendation - antibiotic selection, dose and duration are decisions for the treating clinician based on culture, susceptibility and patient factors.

Side effects & safety profile

Daptomycin must never be used for pneumonia: it is inactivated by lung surfactant and does not achieve efficacy in pulmonary infection. This is a hard contraindication in the approved labelling.

The signature toxicity is skeletal-muscle injury - myopathy with raised creatine phosphokinase (CPK), which requires weekly CPK monitoring; risk rises with concomitant statins, so temporarily stopping statins is often advised. Rare but serious eosinophilic pneumonia and peripheral neuropathy have also been reported.

It is generally well tolerated overall, but because it is renally cleared, the dosing interval is extended in significant renal impairment.

Stacking & combinations

In clinical use daptomycin is sometimes combined with other agents (for example a beta-lactam) for refractory S. aureus bacteraemia, but any such combination is a clinician-directed decision and outside consumer stacking.

Finding Daptomycin vendors

User reviews

Frequently asked questions

References

1. [1] Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus — Fowler VG Jr et al., New England Journal of Medicine 2006. PMID: 16914701. View sourceStudy: Open-label randomized controlled trial (n=246)Daptomycin was non-inferior to standard therapy for S. aureus bacteraemia and right-sided endocarditis.
2. [2] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections — Arbeit RD et al., Clinical Infectious Diseases 2004. PMID: 15227611. View sourceStudy: Pooled phase-3 randomized controlled trialsDaptomycin matched comparator therapy for complicated skin and skin-structure infections.
3. [3] Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections — Steenbergen JN et al., Journal of Antimicrobial Chemotherapy 2005. PMID: 15705644. View sourceStudy: ReviewReviews daptomycin's calcium-dependent membrane-depolarising mechanism and Gram-positive spectrum.
4. [4] Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports — Kim PW et al., Drug Safety 2012. PMID: 22612850. View sourceStudy: Literature review + pharmacovigilance analysisCharacterises daptomycin-associated eosinophilic pneumonia as a recognised, reversible adverse effect.
5. [5] Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program — Figueroa DA et al., Clinical Infectious Diseases 2009. PMID: 19500039. View sourceStudy: Observational clinical programHigh-dose daptomycin was generally well tolerated, with CPK elevation the main monitored toxicity.
6. [6] Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy — Kido K et al., American Journal of Health-System Pharmacy 2019. PMID: 30689699. View sourceStudy: Clinical studyConcurrent statin use is associated with increased daptomycin-related musculoskeletal toxicity.